UK Predictive Genetic Testing Consumer Wellness Genomics Market

ID: MRFR/LS/50118-HCR
200 Pages
Satyendra Maurya
Last Updated: March 28, 2026
UK Predictive Genetic Testing and Consumer Wellness Genomics Market Research Report By Test Type (Predictive Testing, Consumer Genomics, Wellness Genomics), By Application (Breast & Ovarian Cancer, Cardiovascular Screening, Diabetic Screening & Monitoring, Colon Cancer, Parkinsonism/Alzheimer’s Disease, Urologic Screening/Prostate Cancer Screening, Orthopedic & Musculoskeletal, Others), and By Setting Type (Proteomic Testing, Metabolic Testing, Genomic Testing) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Predictive Genetic Testing Consumer Wellness Genomics Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)7.67%
2024 Market Size$ 290.63 Million
2025 Market Size$ 318.57 Million
2035 Market Size$ 655.29 Million

Key Players

23andMe
Genomics England
MyHeritage
Ancestry
Fulgent Genetics
Illumina
Trends
  • Rise of Direct-to-Consumer Testing
  • Integration with Digital Health Platforms
  • Emphasis on Education and Awareness
Opportunities
  • Regulatory Support and Frameworks
  • Growing Awareness of Preventive Healthcare
  • Advancements in Genetic Testing Technologies
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Million)
      1. 4.1.1 Disease Risk Assessment
      2. 4.1.2 Carrier Testing
      3. 4.1.3 Pharmacogenomics
      4. 4.1.4 Nutrigenomics
      5. 4.1.5 Ancestry Testing
    2. 4.2 Healthcare, BY End Use (USD Million)
      1. 4.2.1 Healthcare Providers
      2. 4.2.2 Research Institutions
      3. 4.2.3 Direct-to-Consumer
      4. 4.2.4 Pharmaceutical Companies
      5. 4.2.5 Insurance Companies
    3. 4.3 Healthcare, BY Technology (USD Million)
      1. 4.3.1 Next Generation Sequencing
      2. 4.3.2 Polymerase Chain Reaction
      3. 4.3.3 Microarray Technology
      4. 4.3.4 Sanger Sequencing
      5. 4.3.5 Digital PCR
    4. 4.4 Healthcare, BY Test Type (USD Million)
      1. 4.4.1 Single Gene Testing
      2. 4.4.2 Panel Testing
      3. 4.4.3 Whole Exome Sequencing
      4. 4.4.4 Whole Genome Sequencing
      5. 4.4.5 Targeted Gene Panels
    5. 4.5 Healthcare, BY Consumer Segment (USD Million)
      1. 4.5.1 Health Conscious Individuals
      2. 4.5.2 Families Planning for Children
      3. 4.5.3 Individuals with Family History of Genetic Disorders
      4. 4.5.4 Fitness Enthusiasts
      5. 4.5.5 Aging Population
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 23andMe (GB)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Genomics England (GB)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 MyHeritage (GB)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Ancestry (GB)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Fulgent Genetics (GB)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Illumina (GB)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Invitae (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Color Genomics (GB)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Gene by Gene (GB)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 UK MARKET ANALYSIS BY APPLICATION
    3. 6.3 UK MARKET ANALYSIS BY END USE
    4. 6.4 UK MARKET ANALYSIS BY TECHNOLOGY
    5. 6.5 UK MARKET ANALYSIS BY TEST TYPE
    6. 6.6 UK MARKET ANALYSIS BY CONSUMER SEGMENT
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
    15. 6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
    17. 6.17 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
    19. 6.19 HEALTHCARE, BY TEST TYPE, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY TEST TYPE, 2024 TO 2035 (USD Million)
    21. 6.21 HEALTHCARE, BY CONSUMER SEGMENT, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY CONSUMER SEGMENT, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
      2. 7.2.2 BY END USE, 2026-2035 (USD Million)
      3. 7.2.3 BY TECHNOLOGY, 2026-2035 (USD Million)
      4. 7.2.4 BY TEST TYPE, 2026-2035 (USD Million)
      5. 7.2.5 BY CONSUMER SEGMENT, 2026-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

UK Predictive Genetic Testing Consumer Wellness Genomics Market Segmentation

UK Predictive Genetic Testing Consumer Wellness Genomics Market By Application (USD Million, 2026-2035)

  • Disease Risk Assessment
  • Carrier Testing
  • Pharmacogenomics
  • Nutrigenomics
  • Ancestry Testing

UK Predictive Genetic Testing Consumer Wellness Genomics Market By End Use (USD Million, 2026-2035)

  • UK Predictive Genetic Testing Consumer Wellness Genomics Market Providers
  • Research Institutions
  • Direct-to-Consumer
  • Pharmaceutical Companies
  • Insurance Companies

UK Predictive Genetic Testing Consumer Wellness Genomics Market By Technology (USD Million, 2026-2035)

  • Next Generation Sequencing
  • Polymerase Chain Reaction
  • Microarray Technology
  • Sanger Sequencing
  • Digital PCR

UK Predictive Genetic Testing Consumer Wellness Genomics Market By Test Type (USD Million, 2026-2035)

  • Single Gene Testing
  • Panel Testing
  • Whole Exome Sequencing
  • Whole Genome Sequencing
  • Targeted Gene Panels

UK Predictive Genetic Testing Consumer Wellness Genomics Market By Consumer Segment (USD Million, 2026-2035)

  • Health Conscious Individuals
  • Families Planning for Children
  • Individuals with Family History of Genetic Disorders
  • Fitness Enthusiasts
  • Aging Population

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035